% | $
Quotes you view appear here for quick access.

Astex Pharmaceuticals, AŞ Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • billyteex1 billyteex1 Sep 1, 2007 9:50 PM Flag

    Whatever happened to MP 371?

    Mp-371 is a multi inhibitor. There was talk early that one of the pipeline drugs would be involved in spinout with orathecin and new delivery technology. We will have to wait and see. My gut tells me SUPG is putting together something special that will surprise us all. When Manuso went on record of this being a buying opportunity, although I am offended by this comment, I just feel that he made this comment because soomething important is developing. He also made this comment to SUPG largest institutional investor. CEO's are always conscious of their wording, because anything they state can be over exaggerated one way or the other. We have 4 presentations over the next few weeks, so I think SUPG unvails the last of the divestigers. Again just a feeling I have.

    One other point on spinout. The biggest growth area will be new delivery technology. Another point to remember supg is working on the first protein on protein compound and a cholestrol drug. A breakthrough could come from a direction no one is expecting. I suggest when you have extra time review end of year 10-k, it mentions this delivery technologys. Good news is coming, either in the form of great results from Dacogen, pipeline drug moving to next stage and spinout. Just takes time and I would rather hear this news around the same time ADOPT news is released and EU news.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Thanks, I appreciate that.

      • 1 Reply to lltinvest
      • Partaject Drug Delivery Technology. Partaject drug delivery technology is a drug delivery system that accommodates poorly water-soluble and water-insoluble compounds by encapsulating them with a fatty layer, known as a phospholipid. The Partaject technology involves coating particles of a drug that are of submicron or near micron size with a membrane-forming phospholipid layer, thereby permitting the creation of a suspension of the drug rather than a solution, and its intravenous injection without the use of potentially toxic solubilizing agents. As a result, we believe the Partaject technology may reduce toxicity created by other injectable forms of delivery mechanisms and potentially increase efficacy by facilitating delivery of compounds whose prior intravenous delivery was impractical because of solubility-related formulation difficulties.

        Partaject products under development. Busulfan is currently marketed in an oral dosage form by GlaxoSmithKline for the palliative treatment of chronic myelogenous leukemia. It is used �off-label� as a bone marrow ablating agent prior to bone marrow transplants. In 1998, we completed a Phase I clinical trial of Partaject busulfan at both Johns Hopkins Oncology Center and Duke University Medical Center. A Phase I clinical trial in pediatric bone marrow ablation has been completed in 35 patients at St. Jude�s Children�s Hospital in Memphis.

        Oral Prodrug Delivery Technology�CZ 112. Oral prodrug delivery technology involves administering an inactive compound, known as a prodrug, which is absorbed in the digestive tract and is converted enzymatically to an active agent in the liver. Oral prodrug delivery technology could potentially enable the oral delivery of drugs that are otherwise only used in an intravenous formulation. The resulting active compounds may pass through the systemic circulation and act at peripheral sites. We are applying the oral prodrug delivery technology to compounds selected for their potential either to serve as oral delivery agents for systemically active chemotherapeutic or radio sensitizing drugs previously available only in intravenous form. CZ 112 is an oral prodrug for Orathecin we licensed from Stehlin in November 1999 after initial Phase I testing.